Categories: Health

Pfizer to explore pneumococcal jab with third booster of Covid vaccine

<p>
<strong>Pfizer on Monday announced a study to explore coadministration of its pneumococcal vaccine along with a third dose of the Pfizer-BioNTech Covid-19 vaccine in older adults.<br />
</strong><br />
Pfizer, in a statement, announced that "the first enrolled subjects have received their immunisations as part of a new study in adults ages 65 or older exploring the coadministration of the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech Covid-19 vaccine, currently authorised by the Food and Drug Administration (FDA) under an emergency use authorisation (EUA)".<br />
<br />
The trial aims to describe safety when both vaccines are co-administered, with follow-up six months after vaccination and to describe immune responses produced by each of the vaccines.<br />
<br />
The trial will include 600 adults who will be recruited from the pivotal Phase 3 Pfizer-BioNTech Covid-19 vaccine trial and will have received their second dose of the vaccine at least six months prior to entering the coadministration study.<br />
<br />
The participants will be randomised to one of three groups: 20vPnC plus Pfizer-BioNTech Covid-19 vaccine booster; 20vPnC plus placebo; and Pfizer-BioNTech Covid-19 vaccine booster plus placebo.<br />
<br />
Boosters and new versions of vaccines that target the Covid variants are already being explored by both Pfizer and Moderna.<br />
<br />
Pfizer CEO Albert Bourla had announced that Covid vaccine recipients will "likely" need a third dose between six to 12 months after they're fully vaccinated. The company is now testing a third booster shot of its vaccine on fully vaccinated people.<br />
<br />
US pharmaceutical Moderna in its Phase 2 study found that a third booster shot of its Covid vaccine can rapidly increase the level of antibodies in previously inoculated people.<br />
<br />
The 20vPnC candidate vaccine is in development for the prevention of invasive disease and pneumonia caused by 20 serotypes of Streptococcus pneumoniae in the vaccine in adults ages 18 years and older.</p>

IANS

Recent Posts

Armed Forces reveal details of damage done to Pakistani air bases in retaliation to cross-border attacks

India's retaliation against Pakistan's heavy shelling and attempted drone attacks in Jammu-Kashmir and regions along…

30 minutes ago

Taliban bans chess in Afghanistan over religious concerns

The Taliban has banned chess in Afghanistan due to religious concerns, continuing its opposition to…

58 minutes ago

US State Department welcomes wisdom, prudence, statesmanship shown by India, Pakistan

The US State Department welcomed the understanding reached by India and Pakistan on the cessation…

1 hour ago

10 satellites working to ensure safety and security: ISRO Chief V Narayanan

Indian Space Research Organisation (ISRO) Chairman V Narayanan said that at least 10 satellites are…

2 hours ago

Lord Buddha’s life will always inspire world community towards compassion, peace: PM Modi

Prime Minister Narendra Modi on Monday extended wishes on the occasion of Buddha Purnima and…

3 hours ago

NIA nabs key Khalistani operative involved in 2016 Nabha jail break escape

The National Investigation Agency (NIA) on Sunday arrested a key Khalistani operative Kashmir Singh Galwaddi…

3 hours ago